LXRX stock information

Sector:

Healthcare

Description:

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals, Inc. website

Current Price

$2.75

RSI

39.73

Market Capitalization:

493.9M

Beta:

1.504

Volume:

3,723,021

Analyst Target Price:

$ 16

Economiic Fair Price:

Earnings DateNovember 01, 2022

Report DateAugust 03, 2022

QuarterQ2

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS-0.614

Profit MarginN/A

Revenue Per Share TTM0.001

Return On Equity TTM-0.93

YoY Revenue Growth (TTM)

-60.16 %

YoY Pre Tax Income Growth (TTM)

-135.54 %

YoY Free Cash Flow (TTM)

QoQ Revenue Growth

-85.04 %

QoQ Pre Tax Income Growth

-36.09 %

QoQ Free Cash Flow Growth

-6.99 %

2021 Revenue

$ 298K

-98.76 %

2020 Revenue

$ 24M

-92.55 %

2019 Revenue

$ 322.1M

409.54 %

2018 Revenue

$ 63.2M

-30.03 %

2017 Revenue

$ 90.3M

8.40 %

2016 Revenue

$ 83.3M

2020 Free Cash Flow

$ -143.1M

2019 Free Cash Flow

$ 113.7M

2018 Free Cash Flow

$ -148.7M

2017 Free Cash Flow

$ -185.6M

2016 Free Cash Flow

$ -175.9M

2021 Pre Tax Income

$ -87.8M

-49.82 %

2020 Pre Tax Income

$ -58.6M

-147.19 %

2019 Pre Tax Income

$ 124.1M

202.96 %

2018 Pre Tax Income

$ -120.5M

14.93 %

2017 Pre Tax Income

$ -141.7M

-0.20 %

2016 Pre Tax Income

$ -141.4M

Lexicon Pharmaceuticals, Inc.(LXRX)